MAPT and Alzheimer disease: To determine the effects of Pim1 inhibition on tau pathology, we first immunostained sections from 3xTg-AD Veh and 3xTg-Pim1-inh1 mice with CP13, an antibody that recognizes tau phosphorylated at serine 202.